Moungnoi 2011.

Methods	A retrospective, descriptive cohort study of methylphenidate use for long‐term administration and its impact on growth at 6 months, 1 years, 2 years, 3 years, 4 years, and 5 years' follow‐up
Participants	Number of participants screened: not stated Number of participants included: 96 Number of participants followed up: 6 participants followed up to 5 years Number of withdrawals: more than 50% by 3rd year of follow‐up Diagnosis of ADHD: DSM‐IV (subtype: combined, 100%) Age: mean 8.62 years old (SD 1.70) IQ: not stated Sex: 75 males, 21 females Methylphenidate‐naïve: not stated Ethnicity: not stated Country: Thailand Comorbidity: not stated Comedication: not stated, but children who received other medication continuing more than 3 months were excluded Sociodemographics: not stated Inclusion criteria: Age 6 years and above Start short‐acting methylphenidate medication at any time between 1 January 2000 to 31 31 December 2007 Continued medicine ≥ 1 year Exclusion criteria: ADHD children who received other medications continuing more than 3 months Concomitant genetic or neurological disorders
Interventions	Methylphenidate type: short acting methylphenidate Mean methylphenidate dosage: 6 months= 0.44 mg/kg/day, 1 year = 0.48 mg/kg/day, 2 years = 0.48 mg/kg/day, 3 years = 0.49 mg/kg/day, 4 years = 0.41 mg/kg/day and 5 years = 0.42mg/kg/day Administration schedule: not stated Duration of intervention: ≥ 1 year Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Height and weight, observer, beginning of short‐acting methylphenidate medication, 6 months, 1‐, 2‐, 3‐, 4‐, 5‐year follow‐up
Notes	Sample calculation: yes. Margin of error 5%, estimated prevalence of ADHD 3.5‐5%, CI 95% = sample size 51‐73 Ethics approval: yes, Ethics Committee of the Queen Sirikit National Institute of Child Health Funding/vested interests: none Authors' affiliations: none Key conclusions of the study authors: prolonged medication with short‐acting methylphenidate showed minimal impact on growth only at the first 6 months; however, growth could catch up in the adolescent period Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated